603998.SS SHH
Hunan Fangsheng Pharmaceutical Co., Ltd.
1W: -1.5%
1M: -3.6%
3M: +10.3%
YTD: -16.6%
1Y: -4.2%
3Y: +3.1%
5Y: +94.4%
¥10.36 ($1.55)
+0.10 (+0.97%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$1.8B
+9.1% ▲
5Y CAGR: +10.2%
Gross Profit
$1.3B
+15.2% ▲
5Y CAGR: +10.0%
Operating Income
$285M
+45.3% ▲
5Y CAGR: +24.2%
Net Income
$255M
+36.6% ▲
5Y CAGR: +26.5%
EPS (Diluted)
$0.58
+38.1% ▲
5Y CAGR: +26.4%
EBITDA
$384M
+23.8% ▲
5Y CAGR: +18.9%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.6B | $1.8B | $1.6B | $1.8B |
| YoY Growth | +16.9% | +22.5% | +14.4% | -9.1% | +9.1% |
| Cost of Revenue | $464M | $563M | $586M | $520M | $500M |
| Gross Profit | $815M | $1.0B | $1.2B | $1.1B | $1.3B |
| Gross Margin | 63.7% | 64.1% | 67.3% | 68.1% | 71.8% |
| R&D Expenses | $54M | $51M | $70M | $108M | $139M |
| SG&A Expenses | $516M | $663M | $796M | $806M | $633M |
| Operating Expenses | $693M | $860M | $995M | $913M | $992M |
| Operating Income | $103M | $100M | $332M | $196M | $285M |
| Operating Margin | 8.1% | 6.4% | 18.5% | 12.1% | 16.1% |
| Interest Expense | $17M | $19M | $23M | $21M | $22M |
| Income Before Tax | $69M | $91M | $327M | $203M | $286M |
| Tax Expense | $15M | $21M | $50M | $24M | $36M |
| Net Income | $64M | $70M | $286M | $187M | $255M |
| Net Margin | 5.0% | 4.5% | 16.0% | 11.5% | 14.4% |
| EPS (Diluted) | $0.15 | $0.16 | $0.67 | $0.42 | $0.58 |
| EBITDA | $156M | $188M | $444M | $310M | $384M |
| Shares Outstanding | 429M | 429M | 429M | 445M | 440M |